Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 102.05

+0.3%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (1382)	3/16/2000 10:37:00 PM
From: tommysdad	Read Replies (1) of 3202

Companies have signed up to Incyte's database on a subscription basis. Incyte supplied the data, so INCY will be due to royalties on compounds discovered using that data regardless of patent issues. In fact, it's my understanding that the subscribers are free to patent genes they identify (as to function, etc), but STILL owe INCY the royalties. The problem will only come from unethical companies trying to claim they didn't use INCY's data, even if they had it, but there could be a codicle covering that as well (may be subscriber dependent). But, hey, all scientists are ethical, right? <VBG>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next